STAT | New study raises questions about early-stage cancer therapies for children

Published: 21 February 2018

At this early stage, the potential for harm is real while the benefits are only surrogate measures, said Kimmelman, an associate professor of biomedical ethics at McGill University. One such measure at Phase 1 might be tumor shrinkage, which does not necessarily translate into what people really care about: survival.
Stat News

Back to top